Synthon Pharmaceuticals, Inc.

Synthon Pharmaceuticals, Inc. is the U.S. arm of Synthon, a privately held Dutch pharmaceutical group headquartered in Nijmegen, Netherlands and founded in 1991. The U.S. entity is registered in North Carolina with a principal office in the Research Triangle Park / Durham area. The group is privately owned; in June 2025 it announced an investment from Goldman Sachs Alternatives. Synthon reports approximately 1,600 employees across eight countries, four R&D labs, and four manufacturing sites (Spain, Czech Republic, Argentina, Chile). It does not disclose revenue publicly.

Products / operations. Synthon is an operating company — a vertically integrated developer and manufacturer of complex small-molecule generics and hybrid medicines, running from API development through finished dosage manufacturing and out-licensing. It reports a portfolio of 70-plus molecules supplied to more than 200 customers in roughly 100 countries, with therapeutic focus on oncology, central nervous system, cardiovascular, and multiple sclerosis. Notable programs include glatiramer acetate (a Copaxone equivalent), ozanimod capsules (generic Zeposia), a 505(b)(2) oncology product licensed to Zydus, and generic pomalidomide.

Patent-litigation posture. Synthon is a pure defendant in the tracked data — 0 cases as plaintiff, 3 as defendant — consistent with an operating generic manufacturer defending Hatch-Waxman ANDA suits rather than an NPE asserting patents. All three tracked matters were brought by Celgene (now part of Bristol-Myers Squibb) and cluster in the District of New Jersey and the Middle District of North Carolina, both common venues for ANDA litigation; neither is an Eastern District of Texas plaintiff-friendly NPE venue.

Notable cases. The tracked suits — Celgene v. Synthon Pharmaceuticals (D.N.J., filed June 2018, 2:18-cv-10775), a parallel Middle District of North Carolina action (June 2018), and a second D.N.J. action (April 2019) — arose from Synthon's ANDA No. 210232 for generic pomalidomide capsules, submitted in partnership with Alvogen Pine Brook. Celgene's complaints asserted Orange Book patents including U.S. 8,198,262; 8,673,939; 8,735,428; 8,828,427; and 9,993,467. The New Jersey actions were resolved by a consent judgment and injunction entered by Judge Esther Salas in May 2019, dismissing the claims with prejudice.